Tempus AI Shares Fell After Recent Market Rally
The stock retreated following a broader market decline, impacting investors holding positions in specific ETFs.
Updated on Sept. 18, 2026 in Investing
Live Poll
Is now a good time to invest in volatile high-growth stocks following a sharp rally?
Shares of Tempus AI dropped 4.49% to $76.75 on Friday amid a wider downturn in the Nasdaq and S&P 500 indices. The pullback followed a period of multi-day gains for the company, which recently secured FDA approval for its solid-tumor assay.
Why it matters
The price movement reflects a broader market correction that affected the healthcare sector, which declined 0.5% during the same session. Investors often monitor these fluctuations to gauge how institutional selling pressure, such as flows from ETFs, influences asset volatility.
Tempus AI shares closed at $76.75, which is 16% above the 20-day simple moving average and 35% above the 50-day moving average. Analysts currently forecast an average stock price of $67.08.
The players
Tempus AI
A healthcare technology company providing data-driven clinical insights and solid-tumor assays.
ARK Innovation ETF
An exchange-traded fund that provides investors exposure to companies focused on disruptive innovation.
ARK Genomic Revolution ETF
An exchange-traded fund dedicated to investing in companies poised to benefit from advancements in genomics.
The details
The recent decline occurred as part of a larger trend where the Nasdaq and S&P 500 both fell, creating downward pressure on stocks with high ETF exposure. Tempus AI accounts for 8.04% of the ARK Genomic Revolution ETF and 4.16% of the ARK Innovation ETF, meaning large-scale fund flows can amplify price volatility. While the company management recently highlighted a positive reimbursement outlook, the stock remains subject to support levels at $61.50 and resistance near $79.
Timeline
September 8, 2026: Rothschild initiated coverage on Tempus AI.
September 9, 2026: UBS initiated coverage on Tempus AI.
September 11, 2026: HC Wainwright raised its price forecast.
September 15, 2026: CEO outlined reimbursement benefits at a healthcare conference.
September 18, 2026: Tempus AI stock fell 4.49%.
Money Landscape
The stock's recent volatility follows the patterns established after the 2026 healthcare conference reimbursement disclosures. This movement highlights how individual biotech equities track with sector-wide indices during periods of institutional rebalancing.
Investors should review their exposure to healthcare ETFs, as significant fund outflows can trigger broader price movements for individual holdings. Consult with a financial professional to determine if your current asset allocation aligns with your risk tolerance during market fluctuations.
The takeaway
Market corrections often create meaningful entry or exit points for investors tracking growth-oriented equities. Use this time to check your current positions against analyst price targets and confirm your portfolio remains diversified across different market sectors.
What happens next
The company expects to implement a new pricing structure for all solid-tumor assays starting Jan. 1.
Further reading
For more on managing portfolio volatility, visit our guide to Investing.
Live Poll
Is now a good time to invest in volatile high-growth stocks following a sharp rally?
